Topihealsen.biz
Topihealsen.bizAtenolol

Tenormin (atenolol) dosing, indications, interactions, adverse effects


6.15.2018 by Isaac Mercer

100 mg PO once daily or divided q12hr for 6-9 days after MI No Results Tiredness (13%) Hypotension (10%) Bradycardia (8%).

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

Patients should be warned against interruption or discontinuance of beta-blocker therapy without physician advice.

Excretion: Feces (50%), urine (40-50%).

Lactation: Drug enters breast milk; neonates born to mothers who are receiving atenolol at parturition or breastfeeding may be at risk for hypoglycemia and bradycardia; use with caution.

Atenolol
Tenormin (atenolol) dosing, indications, interactions, adverse effects

Avoid beta-blockers without alpha1-adrenergic receptor blocking activity in patients with Prinzmetal variant angina; unopposed alpha1-adrenergic receptors mediate coronary vasoconstriction and can worsen anginal symptoms.

Because coronary artery disease (CAD) is common and may be unrecognized, beta-blocker therapy must be discontinued slowly, even in patients treated only for hypertension.

Risk of hypoglycemia and bradycardia in neonates born to mothers who receive the drug at parturition or while breastfeeding, especially in premature infants and those with renal impairment.

25-100 mg PO once daily or divided q12hr.

May potentiate hypoglycemia and may mask its signs and symptoms in patients with diabetes mellitus; use caution.

25 mg/day PO; after 1 week, may be increased to 100 mg/day; some patients may require 200 mg/day Secondary prevention.

processing.... Drugs & Diseases atenolol (Rx) Brand and Other Names: Tenormin Classes: Beta-Blockers, Beta-1 Selective Share Print Feedback Close Facebook Twitter LinkedIn Google+ Sections atenolol (Rx) Sections atenolol Dosing & Uses Interactions Adverse Effects Warnings Pregnancy Pharmacology Administration Images Patient Handout Formulary Dosing & Uses Adult Pediatric Geriatric Dosage Forms & Strengths tablet.

2°/3° heart block in patients without pacemaker Cardiogenic shock Sinus bradycardia Sinus node dysfunction Hypersensitivity Uncompensated cardiac failure Pulmonary edema.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

Antinuclear antibodies (ANA), lupus syndrome Visual disturbances, xerophthalmia Raynaud phenomenon.

Cold extremities (0.5- 7%) Postural hypotension (2-4%) Depression (3%) Nausea (2-3%) Dreaming (2%) Drowsiness (2%) Diarrhea (1-2%) Fatigue (1-2%) Leg pain (1-2%) Lethargy (1-2%) Lightheadedness (1-2%) Vertigo (1-2%) Dyspnea (0.4-2%).

Use in pheochromocytoma (alpha blockade required before use of beta blocker).

Avoid abrupt withdrawal; sudden discontinuance can exacerbate angina and lead to MI.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

Half-life: Children, 4.6 hr; adults, 6-7 hr; neonates, <35 hr; end-stage renal disease, 15-35 hr Dialyzable: Yes (HD).

Adding plans allows you to compare formulary status to other drugs in the same class.

50 mg/day PO, beginning up to 3 days before surgery and continued until 7 days after surgery; may be increased to 100 mg/day.

Metabolites: No clinically active metabolites.

50 mg/day PO; after 1 week, may be increased to 100 mg/day PO; some patients may require 200 mg/day Secondary prevention.

Hypersensitivity to catecholamines has been observed during withdrawal.

If angina worsens markedly or acute coronary insufficiency develops, beta-blocker administration should be promptly reinitiated, at least temporarily (in addition to other measures appropriate for unstable angina).

Increased risk of stroke after surgery.

No Results No Results.

25-50 mg/day PO initially; may be increased to 100 mg/day PO.

100 mg PO once daily or divided q12hr for 6-9 days after myocardial infarction (MI) 50-100 mg/day PO Prevention.

25 mg/day PO initially; may be increased to 100 mg/day PO.

CrCl >35 mL/min/1.73 m²: Dose adjustment not necessary tablet.

NA: Information not available.

Administer by slow IV infusion at 1 mg/min, either directly undiluted or diluted with D5W or NS.

May be necessary to initiate dosing at 25 mg/day PO.

Elevated serum hepatic enzymes and bilirubin Impotence, Peyronie disease.

CrCl 15-35 mL/min/1.73 m²: Not to exceed 50 mg/day PO.

Exacerbation or induction of psoriasis reported with beta-blocker use; cause and effect not established Pregnancy category: D.

Onset: Antihypertensive response, 3 hr.

Use with caution in anesthesia or surgery (myocardial depression), bronchospastic disease, cerebrovascular insufficiency, diabetes mellitus, hyperthyroidism or thyrotoxicosis, liver disease, renal impairment, peripheral vascular disease, compromised left ventricular function, advanced age, heart failure.

May cause or exacerbate CNS depression (use with caution in patients with psychiatric illness).

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. From: To:

0.5-1 mg/kg/day PO; not to exceed 2 mg/kg/day or 100 mg/day.

Catatonia, disorientation, emotional lability, hallucinations, headache, impaired performance on neuropsychometric tests, psychoses, short-term memory impairment Purpura, rashes Nausea Thrombocytopenia.

Metabolized to limited extent in liver.

Exacerbation of angina and, in some cases, MI may occur after abrupt discontinuance.

Duration: 12-24 hr (normal renal function).

May mask effects of hyperthyroidism.

Monitor for worsening of heart failure symptoms in patients with compensated heart failure.

Use with caution in patients taking calcium-channel blockers or cardiac glycosides or using inhaled anesthetics.

Ischemic heart disease may be exacerbated after abrupt withdrawal.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

When long-term beta blocker therapy (particularly with ischemic heart disease) is discontinued, dosage should be gradually reduced over 1-2 weeks with careful monitoring.

Hypotension, severe congestive heart failure (CHF), sick sinus syndrome.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

Consider preexisting conditions such as sick sinus syndrome before initiating therapy.

By clicking send, you acknowledge that you have permission to the recipient with this information.

Store intact ampoules at room temperature Protect from light.

Y-site: Meperidine, meropenem, morphine sulfate.

In patients receiving clonidine, atenolol should be discontinued several days before withdrawal of clonidine.

2°/3° atrioventricular (AV) block (1%).

Y-site: Amphotericin B cholesteryl sulfate.

Peak plasma time: 2-4 hr Protein bound: 6-16% Vd: 50-75 L/kg.

The recipient will receive more details and instructions to access this offer.

Use caution in patients with myasthenia gravis; may precipitate or aggravate symptoms or arterial insufficiency in patients with Raynaut's disease and peripheral vascular disease; use caution and monitor for progression of arterial obstruction.

Blocks response to beta-adrenergic stimulation; cardioselective for beta1 receptors at low doses, with little or no effect on beta2 receptors Bioavailability: 46-60%

Admixture in dextrose and NaCl-containing solution is stable for 48 hours.

CrCl <15 mL/min/1.73 m²: Not to exceed 25 mg/day PO.

Atenolol